What TriArm Therapeutics does

TriArm Therapeutics is a clinical-stage cell therapy company developing CAR-T therapies for patients with hematological malignancies and autoimmune diseases. The company operates from a corporate headquarters in San Mateo, California, with a Beijing, China presence, and is structured as a privately-held for-profit entity with 11-50 employees. Its stated mission is to democratize curative CAR-T therapy by addressing the manufacturability constraints and prohibitive costs associated with conventional viral-based CAR-T programs.

The company's core product is the FIT™ (Fast-In-Time) non-viral manufacturing platform, which enables rapid vein-to-vein turnaround in several days at enhanced yield and stemness at a fraction of conventional CAR-T cost. This is complemented by three proprietary technology modules: FlexTune™, which decouples antigen binding from CAR signaling via OppoTAGs adaptors to optimize timing, potency, diversity, polyclonality, persistence and safety; CD30+ FineTune™, a novel CD30+ scFV that amplifies CAR-T expansion magnitude and rapidity while preventing fratricide; and CD3ε FlowTune™, a CD3ε modulator that delivers a gentler cytokine release profile and enables application to autoimmune diseases regardless of treatment chronicity.

As a pre-revenue clinical-stage biopharmaceutical, TriArm's near-term revenue mechanics are not yet established. The company has raised approximately $80M across two disclosed funding rounds (2019: $20M Series 2 led by Panacea Venture and Virtus Inspire Ventures; 2021: $60M with participation from EFung Capital, HT Capital, Junpu, Panacea Venture, and Viventures). Future revenue is expected to flow from commercialization or licensing of approved CAR-T products targeting hematological malignancies and autoimmune diseases, distributed through authorized cell therapy treatment centers. Leadership comprises co-founders Jay Zhang and Jinhua Lu (CEO and CSO respectively) alongside CEO Douglas Williams.

Name

TriArm Therapeutics

Legal name

TriArm Therapeutics

Website

https://triarmbio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

TriArm Therapeutics is a clinical-stage cell therapy company developing CAR-T therapies using a proprietary non-viral manufacturing platform (FIT™) and modular enhancer technologies for patients with hematological malignancies and autoimmune diseases.

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

Keywords

• CAR-T cell therapy
• Non-viral cell therapy
• Immunotherapy development
• Hematological malignancy treatment
• Autoimmune cell therapy

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain

Revenue model

1. CAR-T Cell Therapy Products: As a clinical-stage biopharmaceutical company, TriArm generates revenue through the development and commercialization of novel CAR-T cell therapy products. The company is focused on delivering accessible, cost-effective CAR-T treatments for patients worldwide, targeting hematological malignancies and autoimmune diseases.

Go-to-market motion1 record

Core offering

TriArm Therapeutics is a clinical-stage cell therapy company that develops and commercializes CAR-T immunotherapies using a proprietary non-viral manufacturing platform (FIT™). Its pipeline targets hematological malignancies and autoimmune diseases through a four-pronged technology stack: the FIT™ core non-viral manufacturing platform and three enhancive technologies (FlexTune™, CD30+ FineTune™, and CD3ε FlowTune™) designed to deliver safer, faster, and more cost-effective CAR-T products.

Product overview

TriArm Therapeutics is a clinical-stage cell therapy company offering a unified CAR-T therapy platform centered on its proprietary non-viral FIT™ (Fast-In-Time) manufacturing process. The core platform is complemented by three enhancive technology modules: FlexTune™ for optimizing CAR-T activity through decoupled antigen binding and signaling, CD30+ FineTune™ for enhanced CAR-T expansion and stemness, and CD3ε FlowTune™ for improved safety via gentler cytokine profiles. Together, these technologies aim to deliver better, safer, and more accessible CAR-T products to patients worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• FIT™ (Fast-In-Time) CAR-T Manufacturing Platform Innovative non-viral manufacturing process for CAR-T cell therapy that enables feasible, efficient, and reproducible production with rapid vein-to-vein turnaround in several days, enhanced yield and stemness at reduced cost. Targeted at patients with hematological malignancies and autoimmune diseases worldwide.
• FlexTune™ CAR-T Enhancement Technology Decoupled antigen binding and CAR signaling technology that uses OppoTAGs adaptors to improve polyclonality, persistence, and safety by optimizing CAR-T activity timing, potency, and diversity. Designed to enhance CAR-T cell therapy candidates targeting hematological malignancies and autoimmune diseases.
• CD30+ FineTune™ CAR-T Enhancement Technology Novel CD30+ scFV technology that amplifies the rapidity and magnitude of CAR-T expansion. Uses proprietary manufacturing and CAR design to prevent fratricide and produce more youthful, stem-like CAR-T cells for hematological malignancy and autoimmune indications.
• CD3ε FlowTune™ CAR-T Enhancement Technology Breakthrough CD3ε modulator providing a gentler cytokine release profile by restoring natural TCR signaling in a self-restrained mechanism. Enhances therapeutic index and affords utility in various autoimmune diseases regardless of treatment chronicity.

Quantifiable outcome

• Rapid vein-to-vein turnaround in several days
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Cellectis: Clinical-stage gene-edited allogeneic CAR-T developer with TALEN-based platform. Comparable to TriArm in pursuing non-conventional (non-viral) cell engineering approaches and platform-based CAR-T development.
• CRISPR Therapeutics: Clinical and commercial-stage gene-edited cell therapy company with partnered CAR-T programs (CTX112, CASGEVY). Comparable in pursuing next-generation engineered CAR-T platforms and pushing into autoimmune indications.
• Kyverna Therapeutics: Clinical-stage CAR-T developer focused on autoimmune diseases, recently IPO'd and partnered with leading pharma. Comparable to TriArm in target indication strategy and clinical-stage cell therapy positioning.
• Precision Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T candidates using ARCUS gene editing platform. Comparable in pursuing differentiated cell therapy manufacturing with autoimmune and oncology indications.
• Fate Therapeutics: Clinical-stage iPSC-derived NK and T-cell therapy developer with proprietary manufacturing platform. Comparable in platform-based approach to cell therapy manufacturing and multi-program pipeline strategy.
• Allogene Therapeutics: Leading allogeneic CAR-T developer with multiple clinical programs across hematological malignancies. Directly comparable as a CAR-T-focused clinical-stage company competing in the same target indications as TriArm.
• Caribou Biosciences: Clinical-stage allogeneic CAR-T developer using CRISPR-edited cell platforms. Directly comparable to TriArm as a similarly-sized cell therapy company pursuing next-generation CAR-T modalities with proprietary manufacturing differentiation.
• Cabaletta Bio: Clinical-stage cell therapy company developing CAR-T candidates for autoimmune diseases, directly overlapping with TriArm's stated autoimmune expansion strategy via CD3ε FlowTune™. Highly relevant for indication overlap and platform philosophy.

Broad incumbents

• Kite Pharma (Gilead): Commercial-stage leader in autologous CAR-T therapy (Yescarta, Tecartus) and a wholly owned Gilead subsidiary. Sets the competitive benchmark TriArm must beat on cost, speed, and scalability in CAR-T.
• Novartis (Kymriah franchise): First-approved CAR-T therapy (Kymriah) and a major pharma incumbent in cell therapy. Comparable as the established competitor TriArm's non-viral platform is positioned against on cost and manufacturing efficiency.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TriArm Therapeutics